The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.
Participants' parent(s)/Legally acceptable representative [LAR(s)] who, in the opinion of the investigator, can and will comply with all protocol requirements.
Written or witnessed/thumb printed informed consent obtained from the participants' parent(s)/LAR(s) prior any study-specific procedure is performed.
A male or female between, and including, 12 to15 Months of age at the time of the study intervention administration.
Healthy participants or medically stable patients as established by medical history and clinical examination before entering the study.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
Hypersensitivity to latex.
History of microbiologically proven Invasive pneumococcal Disease (IPD).
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.